ProShare Advisors LLC lessened its holdings in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 6.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 466,806 shares of the medical instruments supplier’s stock after selling 33,856 shares during the period. ProShare Advisors LLC owned about 0.64% of West Pharmaceutical Services worth $153,761,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently made changes to their positions in WST. Fidelis Capital Partners LLC acquired a new position in West Pharmaceutical Services during the 1st quarter worth approximately $27,000. Crewe Advisors LLC grew its stake in shares of West Pharmaceutical Services by 322.7% during the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 71 shares during the last quarter. Quarry LP increased its holdings in shares of West Pharmaceutical Services by 155.3% during the fourth quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock worth $34,000 after buying an additional 59 shares in the last quarter. Hazlett Burt & Watson Inc. bought a new position in shares of West Pharmaceutical Services in the 1st quarter valued at $40,000. Finally, Northwest Investment Counselors LLC bought a new position in shares of West Pharmaceutical Services in the 1st quarter valued at $40,000. Institutional investors own 93.90% of the company’s stock.
West Pharmaceutical Services Trading Down 1.0 %
NYSE WST opened at $308.15 on Friday. The company has a market cap of $22.45 billion, a price-to-earnings ratio of 40.65, a price-to-earnings-growth ratio of 10.58 and a beta of 1.01. West Pharmaceutical Services, Inc. has a twelve month low of $265.00 and a twelve month high of $413.70. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03. The business’s fifty day moving average is $303.37 and its 200 day moving average is $337.31.
Insider Buying and Selling at West Pharmaceutical Services
In other news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction on Monday, August 19th. The shares were sold at an average price of $300.00, for a total transaction of $308,700.00. Following the transaction, the vice president now owns 1,478 shares in the company, valued at $443,400. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.53% of the company’s stock.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Featured Stories
- Five stocks we like better than West Pharmaceutical Services
- There Are Different Types of Stock To Invest In
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- MarketBeat Week in Review – 9/16 – 9/20
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.